HS235, a Novel Activin Signaling Inhibitor, is Highly Efficacious in Preclinical Models of Pulmonary Hypertension (PH) and Heart Failure (HF) - Amsterdam 2025

Pulmonary hypertension: novel pathogenic pathways, noninvasive surrogate markers and possible therapeutic benefit

Chair(s): Yochai Adir, Katarina Zeder

Session type: Oral presentation

HS235, a Novel Activin Signaling Inhibitor, is Highly Efficacious in Preclinical Models of Pulmonary Hypertension (PH) and Heart Failure (HF)

Maureen OConnor

EVENTS HOME

Previous presentation

Next presentation

Session content

Late Breaking Abstract - StratosPHere 1 study - a novel BMP target engagement biomarker panel for use in clinical trials demonstrates sotatercept alters gene expression in pulmonary arterial hypertension

Rowena Jones

Replay

Poster

Abstract

Slides

Mechanistic Study on Luteolin-Mediated SIRT1 Deacetylation in Mitochondrial Energy Metabolism Remodeling in Pulmonary Arterial Hypertension

Hong Chen

Replay

Poster

Abstract

Slides

Rare Variants in RYR1/RYR2 Associated with CTEPH Occurrence: Insights from a Large Whole-Genome Sequencing Analysis

Zhenguo Zhai

Replay

Poster

Abstract

Slides

Predicting mortality with right ventricular function in pulmonary hypertension associated with lung disease

Ze Ming Goh

Replay

Poster

Abstract

Slides

HS235, a Novel Activin Signaling Inhibitor, is Highly Efficacious in Preclinical Models of Pulmonary Hypertension (PH) and Heart Failure (HF)

Maureen Oconnor

Replay

Poster

Abstract

Slides

Clinical relevance of a novel non-invasive surrogate of pulmonary exercise hemodynamics

Teresa John

Replay

Poster

Abstract

Slides

Integrin ?5?1: a promising target for right ventricular dysfunction in pulmonary arterial hypertension

Sarah-eve Lemay

Replay

Abstract

Slides

Impact of comorbidities on therapeutic response in patients with idiopathic pulmonary arterial hypertension

Benedetta Pozzato

Replay

Poster

Abstract

Slides

Endothelial cells in chronic thromboembolic pulmonary hypertension exhibit cytoskeletal alterations.

Miriam Peracaula

Poster

Abstract

Slides

ALG-801 demonstrates superior therapeutic efficacy in sugen-hypoxia model of pulmonary hypertension

Hq Han

Replay

Poster

Abstract

Slides

Discussion and Q&A

Replay

CDN Connection Issue

The ERS Congress 2025, Amsterdam

#{title}